Hypothalamic obesity in a patient with craniopharyngioma: Dysregulation of neurohormonal control of energy balance

Current Opinion in Pediatrics

Volumn 17, Issue 2, 2005, Pages 275-279

  Maniatis, Aristides K ^a   Simmons, Jill H ^a   Zeitler, Philip S ^a  

^a CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN ACETATE; DEXAMPHETAMINE; GROWTH HORMONE; HYDROCORTISONE; LEVOTHYROXINE; SIBUTRAMINE;

ADRENAL INSUFFICIENCY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; CLINICAL FEATURE; CRANIOPHARYNGIOMA; DIABETES INSIPIDUS; DISEASE COURSE; ENERGY BALANCE; EYE PAIN; GROWTH HORMONE DEFICIENCY; HEADACHE; HORMONAL REGULATION; HUMAN; HYPOTHYROIDISM; MALE; OBESITY; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

APPETITE; BODY WEIGHT; CHILD; CRANIOPHARYNGIOMA; GROWTH HORMONE; HEADACHE; HUMANS; HYPOTHALAMIC DISEASES; MALE; NEOPLASM RECURRENCE, LOCAL; OBESITY; PITUITARY NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VOMITING;

EID: 17144371022     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000156268.40887.0a     Document Type: Article

References (33)

1. Srinivasan S, Ogle G, Garnett S, et al. Features of the metabolic syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab 2004; 89:81-86.
2. Muller H, Bueb K, Bartels U, et al. Obesity after childhood craniopharyngioma: German multicenter study on pre-operative risk factors and quality of life. Klin Padiatr 2001; 213:244-249.
3. Lustig R, Post S, Srivannaboon K, et al. Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab 2003; 88:611-616.
4. Muller H, Heinrich M, Bueb K, et al. Perioperative dexamethasone treatment in childhood craniopharyngioma: influence on short-term and long-term weight gain. Exp Clin Endocrinol Diabetes 2003; 111:330-334.
5. Lustig R, Hinds P, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2003; 88:2586-2592.
6. De Vile C, Grant D, Hayward R, et al. Obesity in childhood craniopharyngioma: relation to post-operative hypothalamic damage shown by magnetic resonance imaging. J Clin Endocrinol Metab 1996; 81:2734-2737.
7. Skorzewska A, Lal S, Waserman J, et al. Abnormal food-seeking behavior after surgery for craniopharyngioma. Neuropsychobiology 1989; 21:17-20.
8. Harz K, Muller H, Waldeck E, et al. Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. J Clin Endocrinol Metab 2003; 88:5227-5231.
9. Flier J. Clinical Review 94. What's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab 1998; 83:1407-1413.
10. Porte D, Baskin D, Schwartz M. Leptin and insulin action in the central nervous system. Nutr Rev 2002; 60:S20-S29.
11. Pritchard L, Turnbull A, White A. Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signaling and obesity. J Endocrinol 2002; 172:411-421.
12. Pi-Sunyer F, Laferrere B, Aronne L, et al. Therapeutic controversy: obesity - a modern-day epidemic. J Clin Endocrinol Metab 1998; 84:3-12.
13. Savoye M, Dziura J, Castle J, et al. Importance of plasma leptin in predicting future weight gain in obese children: a two-and-a-half-year longitudinal study. Int J Obes 2002; 26:942-946.
14. Heptulla R, Smitten A, Teague B, et al. Temporal patterns of circulating leptin levels in lean and obese adolescents: relationships to insulin, growth hormone, and free fatty acids rhythmicity. J Clin Endocrinol Metab 2001; 86:90-96.
15. Dornonville de la Cour C, Bjorkqvist M, Sandvik A, et al. A-like cells in the rat stomach contain ghrelin and do not operate under gastric control. Regul Pept 2001; 99:141-150.
16. Horvath T, Diano S, Sotonyi P, et al. Minireview: ghrelin and the regulation of energy balance: a hypothalamic perspective. Endocrinology 2001; 142:4163-4169.
17. Lustig R. The neuroendocrinology of obesity. Endocrinol Metab Clin North Am 2001; 30:765-785.
18. Berazzoni R, Zanetti M, Stebel M, et al. Hyperleptinemia prevents increased plasma ghrelin concentration during short-term moderate caloric restriction in rats. Gastroenterology 2003; 124:1188-1192.
19. Arvat E, Di Vito L, Broglio F, et al. Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand strongly stimulates GH secretion in humans. J Endocrinol Invest 2000; 23:493-495.
20. Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural GH secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001; 86:1169-1174.
21. Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001; 86:5083-5086.
22. Cummings D, Purnell J, Frayo R, et al. A pre-prandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50:1714-1719.
23. Tschop M, Wawarta R, Riepl R, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001; 24:19-21.
24. Otto B, Cuntz U, Fruehauf E, et al. Weigh: gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001; 145:669-673.
25. Shiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87:240-244.
26. Haqq A, Farooqi I, O'Rahilly S, et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 2003; 88:174-178.
27. Neary N, Small C, Bloom S. Gut and mind. Gut 2003; 52:918-921.
28. Batterham R, Cohen M, Ellis S, et al. Inhibition of food intake in obese subjects by peptide YY 3-36. N Engl J Med 2003; 349:941-948.
29. Batterham R, Cowley M, Small C, et al. Gut hormone PYY 3-36 physiologically inhibits food intake. Nature 2002; 418:650-654.
30. Boston B. Pro-opiomelanocortin and weight regulation: from mice to men. J Pediatr Endocrinol Metab 2001; 14:1409-1416.
31. Lustig R. The neuroendocrinology of obesity. Endocrinol Metab Clin North Am 2001; 30:765-785.
32. Mason P, Krawiecki N, Meacham L. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med 2002; 156:887-892.
33. Berkowitz R, Wadden T, Tershakovec A, et al. Behavior therapy and sibutramine for the treatment of adolescent obesity, a randomized controlled trial. JAMA 2003; 289:1805-1812.